Platelet BioGenesis is the leader in stem cell-derived, on-demand human platelets (PLTs+™) and platelet-based therapeutics.
Platelet BioGenesis is developing technology to produce the world’s first donor-independent human platelets from human induced pluripotent stem cells.
Platelet BioGenesis was founded in 2014 by Jonathan Thon, Joseph Italiano, & Sven Karlsson and is based in Cambridge, Massachusetts.
Platelet BioGenesis seeks to extend the healing and therapeutic power of platelets by advancing and commercializing the science of making functional human platelets on-demand from induced pluripotent stem cells.
Platelet BioGenesis (PBG) has created the only platform that can generate human platelets at scale. The stem cell-derived, on-demand platelets will be the first donor-independent source of platelets to address the chronic shortage worldwide.
Platelet BioGenesis is backed by investors including Ziff Capital Partners (ZCP), Qiming Venture Partners USA, Nest.Bio Ventures & eCoast Angels among others. The company raised $26M in its latest "Series A" financing on Sep 9, 2019. This brings Platelet BioGenesis' total funding to $40.6M to-date.